Paul Tudor Jones Graphite Bio, Inc. Transaction History

Tudor Investment Corp Et Al

  • $19.2 Billion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021
SELL
$15.81 - $28.39 $189,720 - $340,680
-12,000 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$18.5 - $30.73 $222,000 - $368,760
12,000 New
12,000 $369,000

Others Institutions Holding GRPH

# of Institutions
3
Shares Held
637K
Call Options Held
0
Put Options Held
0
View Full List

About Graphite Bio, Inc.

GRPH Quotes by TradingView
  • Ticker GRPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,211,200
  • Description
  • Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...
More about GRPH
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email